FrancophonIA/ELRC3.0 huggingface dataset:
English: Systemic exposures (AUC) at the no-observed-adverse-effect level (NOAEL) were 79- and 126-fold higher than in humans, for indacaterol and glycopyrronium respectively.
Estonian: plasmakontsentratsiooni (AUC) väärtus oli indakateroolile ja glükopürrooniumile täheldatava kahjuliku toimeta doosist (NOAEL) vastavalt 79- ja 126- korda kõrgemad kui inimestel soovitatava annuse kasutamisel saavutatav plasmatase.
English: A moderate mean increase in total systemic exposure (AUClast) of up to 1.4-fold was seen in subjects with mild and moderate renal impairment and up to 2.2-fold in subjects with severe renal impairment and end-stage renal disease.
Estonian: Kerge ja keskmise raskusega neerukahjustusega isikutel täheldati AUCinf kuni 1,4-kordset ning raske neerukahjustuse ja lõppstaadiumis neeruhaigusega patsientidel kuni 2,2-kordset mõõdukat keskmist suurenemist.
English: 24 x 1 capsules + 1 inhaler.
Estonian: 24 x 1 kapslit + 1 inhalaator.
English: Ultibro Breezhaler - tiotropium
Estonian: Ultibro Breezhaler - tiotroopium
English: Due to the very low contribution of the urinary pathway to total body elimination of indacaterol maleate, a study in renal impaired subjects was not performed.
Estonian: Kuna neerudel on ravimi eliminatsioonis väga väike roll, siis neerukahjustusega patsientidel uuringut läbi ei viidud.
English: Multipack: 96 (4 packs of 24 x 1) capsules + 4 inhalers.
Estonian: Mitmikpakend: 96 (4 pakendit, mis sisaldavad 24x1) kapslit + 4 inhalaatorit.
English: Each capsule contains 143 micrograms of indacaterol maleate equivalent to 110 micrograms of indacaterol and 63 micrograms of glycopyrronium bromide equivalent to 50 micrograms of glycopyrronium.
Estonian: Üks kapsel sisaldab 143 mikrogrammi indakateroolmaleaati, mis vastab 110 mikrogrammile indakateroolile, ja 63 mikrogrammi glükopürrooniumbromiidi, mis vastab 50 mikrogrammile glükopürrooniumile.
English: A moderate mean increase in total system exposure (AUClast) to glycopyrronium of up to 1.4-fold was seen in subjects with mild and moderate renal impairment and up to 2.2-fold in subjects with severe renal impairment and end-stage renal disease.
Estonian: Kerge ja keskmise raskusega neerukahjustusega isikutel täheldati glükopürrooniumi plasmakontsentratsiooni (AUCinf) kuni 1,4-kordset ning raske neerukahjustuse ja lõppstaadiumis neeruhaigusega patsientidel kuni 2,2-kordset suurenemist.
English: • itching or rash.
Estonian: • sügelus või lööve.
English: Systemic exposures (AUC) at the no-observed-adverse-effect level (NOAEL) for myocardial lesions were 64- and 59-fold higher than in humans, for each component respectively.
Estonian: Müokardi kahjustuse korral oli plasmakontsentratsiooni (AUC) väärtus vastavalt igale koostisosale täheldatava kahjuliku toimeta doosist (NOAEL) 64- ja 59-korda kõrgemad kui inimestel soovitatava annuse kasutamisel saavutatav plasmatase.
English: Common (may affect up to 1 in 10 people)
Estonian: Sageli esinevad kõrvaltoimed (võivad esineda kuni 1 inimesel 10-st)
English: Indacaterol is a long-acting beta2-adrenergic agonist for once-daily administration.
Estonian: Indakaterool on pikatoimeline beeta-2-adrenomimeetikum annustamiseks üks kord ööpäevas.
English: As long as the capsule is empty you have received enough of your medicine.
Estonian: Olete piisavalt ravimit kätte saanud juhul kui kapsel on tühi.
English: Inhaler body and cap are made from acrylonitrile butadiene styrene, push buttons are made from methyl metacrylate acrylonitrile butadiene styrene.
Estonian: Inhalaatori korpus ja kork on valmistatud akrülonitriilbutadieenstüreenist, nupud on valmistatud metüülmetakrülaat-akrülonitriilbutadieenstüreenist.
English: The effects of Ultibro Breezhaler on QTc interval were investigated in healthy volunteers after inhalation of Ultibro Breezhaler up to 4 times the recommended therapeutic dose in four dose steps each separated by one hour.
Estonian: Toimet QTc-intervallile uuriti tervetel täiskasvanutel manustades Ultibro Breezhalerit annuses, mis vastas 4-kordsele soovitatavale terapeutilisele annusele ning manustati neljas järgus, ühetunnise intervalliga.
English: Ultibro Breezhaler 85 micrograms/43 micrograms inhalation powder hard capsules
Estonian: Ultibro Breezhaler 85 mikrogrammi/43 mikrogrammi inhalatsioonipulber kõvakapslis
English: Ultibro Breezhaler increased post-dose trough FEV1 by 200 ml compared to placebo at the 26-week primary endpoint (p<0.001) and showed statistically significant increases compared to each monotherapy component treatment arm (indacaterol and glycopyrronium) as well as the tiotropium treatment arm, as shown in the below table.
Estonian: Võrreldes platseeboga oli 26 nädala pärast (esmane tulemusnäitaja) Ultibro Breezhaleriga suurenenud minimaalne annustamisjärgne FEV1 200 ml võrra (p<0,001) ning statistiliselt oluline tõus oli võrreldes monoteraapiaga nii aktiivse raviaine uuringuõlas (indakaterool ja glükopürroonium) kui ka tiotroopiumi uuringuõlas, nagu näidatud järgnevas tabelis.
English: Based on the clinical pharmacokinetic characteristics of its monotherapy components, Ultibro Breezhaler can be used at the recommended dose in patients with mild to moderate renal impairment.
Estonian: Ultibro Breezhaleri üksikute koostisosade kliinilisi farmakokineetilisi omadusi arvestades võib Ultibro Breezhalerit kasutada soovitatavas annuses kerge kuni mõõduka maksakahjustusega patsientidel.
English: Ultibro Breezhaler statistically significantly reduced breathlessness as evaluated by the Transitional Dyspnoea Index (TDI); it demonstrated a statistically significant improvement in the TDI focal score at week 26 compared to placebo (LS mean treatment difference 1.09, p<0.001), tiotropium (LS mean treatment difference 0.51, p=0.007) and fluticasone/salmeterol (LS mean treatment difference 0.76, p=0.003).
Estonian: Ultibro Breezhaler vähendas võrreldes platseeboga statistiliselt oluliselt TDI (Transitional Dyspnoea Index) põhjal hinnatud hingeldust ja saavutas statistiliselt olulise TDI skoori paranemise 26. nädalal võrreldes platseeboga (vähimruutude keskmise erinevus ravi korral 1,09, p<0,001), tiotroopiumiga (vähimruutude keskmise erinevus ravi korral 0,51, p=0,007) ja flutikasooni/salmeterooliga (vähimruutude keskmise erinevus ravi korral 0,76, p=0,003).
English: Cardiac disorders Ischaemic heart disease
Estonian: Südame häired Südame isheemiatõbi
English: The magnitude of the effect was dependent on the degree of reversibility of airflow limitation at baseline (tested by administration of a short-acting muscarinic antagonist bronchodilator and a short-acting beta2-agonist bronchodilator): Patients with the lowest degree of reversibility at baseline (<5%) generally exhibited a lower bronchodilator response than patients with a higher degree of reversibility at baseline (≥5%).
Estonian: Kõige väiksema taaspöörduvuse määraga (<5%) patsientidel oli nõrgem vastus bronhodilataatoritele, kui patsientidel, kellel oli suurem taaspöörduvuse määr (≥5%).
English: Multipacks containing 96 (4 packs of 24x1) hard capsules and 4 inhalers.
Estonian: Mitmikpakend, mis sisaldab 96 (4 pakendit, igas 24x1) kõvakapslit ja 4 inhalaatorit.
English: 6 or 10 Ultibro Breezhaler capsules to be used in the inhaler
Estonian: • Ühte või mitut blisterpakendit, millest igaühes on kas 6 või 10 Ultibro Breezhaleri kapslit inhalaatorisiseks kasutamiseks
English: 6 x 1 capsules + 1 inhaler.
Estonian: 6 x 1 kapslit + 1 inhalaator.
English: • chest pain.
Estonian: • valu rinnus.
English: The amount of indacaterol and glycopyrronium inhaled is 85 micrograms (equivalent to 110 micrograms of indacaterol maleate) and 43 micrograms (equivalent to 54 micrograms of glycopyrronium bromide), respectively.
Estonian: Inhaleeritav indakaterooli ja glükopürrooniumi kogus on vastavalt 85 mikrogrammi (vastab 110 mikrogrammile indakateroolmaleaadile) ja 43 mikrogrammi (vastab 54 mikrogrammile glükopürrooniumbromiidile).
English: Based on the clinical pharmacokinetic characteristics of its monotherapy components, Ultibro Breezhaler can be used at the recommended dose in patients with mild and moderate hepatic impairment.
Estonian: Ultibro Breezhaler üksikute koostisosade kliinilisi farmakokineetilisi omadusi arvestades võib Ultibro Breezhalerit kasutada soovitatavas annuses kerge kuni mõõduka neerukahjustusega patsientidel.
English: Each inhaler should be disposed of after all capsules have been used.
Estonian: Inhalaatori hävitamine pärast kasutamist Iga inhalaator tuleb hävitada pärast seda, kui kõik kapslid on kasutatud.
English: Ask your doctor or pharmacist for advice before using any medicine.
Estonian: Enne mis tahes ravimi kasutamist pidage nõu oma arsti või apteekriga.
English: What Ultibro Breezhaler is used for
Estonian: Milleks Ultibro Breezhalerit kasutatakse
English: • cough.
Estonian: • pearinglus.
English: • dizziness.
Estonian: • köha.
English: How much Ultibro Breezhaler to use
Estonian: Kui palju Ultibro Breezhalerit kasutada
English: Multipack comprising 4 packs (24 capsules + 1 inhaler)
Estonian: 4 pakendist (24 kapslit + 1 inhalaator) koosnev mitmikpakend
English: Multipack: 150 (15 packs of 10 x 1) capsules + 15 inhalers.
Estonian: Mitmikpakend: 150 (15 pakendit, mis sisaldavad 10x1) kapslit + 15 inhalaatorit.
English: Heart rate in COPD patients at supratherapeutic dose levels was investigated.
Estonian: Südame löögisagedust uuriti soovitatavast annusest kõrgemaid annuseid saavatel KOKi patsientidel.
English: What Ultibro Breezhaler is and what it is used for What you need to know before you use Ultibro Breezhaler How to use Ultibro Breezhaler Possible side effects
Estonian: 1. Mis ravim on Ultibro Breezhaler ja milleks seda kasutatakse 2. Mida on vaja teada enne Ultibro Breezhaleri kasutamist 3.
English: No data are available for subjects with severe hepatic impairment.
Estonian: Andmed puuduvad raske maksakahjustusega patsientide kohta.
English: What Ultibro Breezhaler contains - The active substances are indacaterol (as maleate) and glycopyrronium bromide.
Estonian: - Toimeained on indakaterool (maleaadina) ja glükopürrooniumbromiid.
English: How to use Ultibro Breezhaler
Estonian: Kuidas Ultibro Breezhalerit kasutada
English: 90 capsules + 1 inhaler
Estonian: 90 kapslit + 1 inhalaator
English: Multipack: 150 (25 packs of 6 x 1) capsules + 25 inhalers.
Estonian: Mitmikpakend: 150 (25 pakendit, mis sisaldavad 6x1) kapslit + 25 inhalaatorit.
English: - you have diabetes.
Estonian: - kui teil on suhkurtõbi.
English: • nose bleeds.
Estonian: • nina verejooks.
English: Multipack comprising 25 packs (6 capsules + 1 inhaler)
Estonian: 25 pakendist (6 kapslit + 1 inhalaator) koosnev mitmikpakend
English: How to store Ultibro Breezhaler
Estonian: Kuidas Ultibro Breezhalerit säilitada
English: Studies in subjects with severe hepatic impairment were not performed.
Estonian: Raske maksakahjustusega patsientidel ei ole uuringuid läbi viidud.
English: EXP The inhaler in each pack should be disposed of after all capsules in that pack have been used.
Estonian: EXP Pakendis olev inhalaator tuleb hävitada, kui kõik kapslid on kasutatud.
English: Use of rescue medication
Estonian: RAVIMI VÄLJASTAMISTINGIMUSED
English: Gastrointestinal disorders Dyspepsia
Estonian: Beetaadrenoblokaatorid
English: • irregular heartbeat.
Estonian: • korrapäratu südametegevus.
English: Dental caries
Estonian: Hambakaaries
English: Therefore, Ultibro Breezhaler should only be used during pregnancy if the expected benefit to the patient justifies the potential risk to the foetus.
Estonian: Indakaterool võib pärssida sünnitustegevust emaka silelihaseid lõõgastava toime tõttu.Seega tohib Ultibro Breezhalerit raseduse ajal kasutada ainult juhul, kui oodatav kasu patsiendile õigustab võimalikku riski lootele.
English: Indacaterol and its metabolites transferred rapidly into the milk of lactating rats.Indacaterol was not embryotoxic or teratogenic in rats or rabbits.
Estonian: Indakaterool ei olnud rottidel või küülikutel embrüotoksilise või teratogeense toimega.
English: Multipacks containing 150 (25 packs of 6x1) hard capsules and 25 inhalers.
Estonian: Mitmikpakend, mis sisaldab 150 (25 pakendit, igas 6x1) kõvakapslit ja 25 inhalaatorit.
English: (same class) to those in Ultibro Breezhaler (see section “Other medicines and Ultibro
Estonian: - kui te kasutate oma kopsuhaiguse raviks teisi ravimeid, mis sisaldavad Ultibro Breezhaleri toimeainetele sarnaseid toimeaineid (sama ravimite rühm) (vt lõik „Muud ravimid ja Ultibro
English: Ultibro Breezhaler 85 micrograms/43 micrograms inhalation powder, hard capsules indacaterol/glycopyrronium
Estonian: Ultibro Breezhaler 85 mikrogrammi/43 mikrogrammi inhalatsioonipulber kõvakapslis indacaterolum/glycopyrronium
English: - Do not swallow the capsules.
Estonian: - Ärge neelake kapsleid alla.
English: What Ultibro Breezhaler is
Estonian: Mida Ultibro Breezhaler sisaldab
English: Each delivered dose (the dose that leaves the mouthpiece of the inhaler) contains 110 micrograms of indacaterol maleate equivalent to 85 micrograms of indacaterol and 54 micrograms of glycopyrronium bromide equivalent to 43 micrograms of glycopyrronium.
Estonian: Üks inhaleeritav annus (annus, mis väljutatakse inhalaatori huulikust) sisaldab 110 mikrogrammi indakateroolmaleaati, mis vastab 85 mikrogrammile indakateroolile ja 54 mikrogrammi glükopürrooniumbromiidi, mis vastab 43 mikrogrammile glükopürrooniumile.
English: Do not swallow the capsule.
Estonian: Ärge kapslit alla neelake.
English: Ultibro Breezhaler can be used at the recommended dose in elderly patients (75 years of age and older).
Estonian: Eakatel patsientidel (75-aastased ja vanemad) võib Ultibro Breezhalerit kasutada soovitatavas annuses.
English: If you get any side effects, talk to your doctor, pharmacist or nurse.
Estonian: Kui teil tekib ükskõik milline kõrvaltoime, pidage nõu oma arsti, apteekriga või meditsiiniõega.
English: - you have kidney problems.
Estonian: - kui teil on probleeme neerudega.
English: Multipack comprising 15 packs (10 capsules + 1 inhaler)
Estonian: 15 pakendist (10 kapslit + 1 inhalaator) koosnev mitmikpakend
English: Do not swallow capsules.
Estonian: Kapsleid mitte neelata.
English: Ultibro Breezhaler - placebo
Estonian: Ultibro Breezhaler - platseebo
English: Thus for bronchodilation in both peripheral and central airways of the human lung a combination of a beta2-adrenergic agonist and a muscarinic antagonist may be beneficial.
Estonian: Seetõttu võib toimida beetaagonisti ja muskariiniretseptorite antagonisti kombinatsioon paremini saavutamaks bronhilõõgastust inimese kopsus nii perifeersetes kui tsentraalsetes hingamisteedes.
English: 30 capsules + 1 inhaler
Estonian: 30 kapslit + 1 inhalaator
English: Multipacks containing 150 (15 packs of 10x1) hard capsules and 15 inhalers.
Estonian: Mitmikpakend, mis sisaldab 150 (15 pakendit, igas 10x1) kõvakapslit ja 15 inhalaatorit.
English: • tiredness.
Estonian: • kurguvalu.
English: - medicines that lower the amount of potassium in your blood.
Estonian: - vere kaaliumisisaldust alandavad ravimid.
English: 10 x 1 capsules + 1 inhaler.
Estonian: 10x1 kapslit + 1 inhalaator.
English: In COPD patients both systemic exposure and total urinary excretion of glycopyrronium at pharmacokinetic steady state increased about dose-proportionally over the (delivered) dose range of 44 to 176 micrograms.
Estonian: Annusevahemiku 44...176 mikrogrammi kasutamisel suurenesid KOKi patsientidel glükopürrooniumi süsteemne plasmakontsentratsioon ja kogu eritumine uriiniga püsiseisundis ligikaudu proportsionaalselt annusega.
English: The delivered dose (the dose that leaves the mouthpiece of the inhaler) is equivalent to 85 micrograms of indacaterol (equivalent to 110 micrograms of indacaterol maleate) and 43 micrograms of glycopyrronium (equivalent to 54 micrograms of glycopyrronium bromide).
Estonian: Inhaleeritav annus (annus, mis väljub inhalaatori huulikust) vastab 85 mikrogrammile indakateroolile (vastab 110 mikrogrammile indakateroolmaleaadile) ja 43 mikrogrammile glükopürrooniumile (vastab 54 mikrogrammile glükopürrooniumbromiidile).
English: • dental caries.
Estonian: • lihasspasm.
English: Other medicines and Ultibro Breezhaler
Estonian: Mis ravim on Ultibro Breezhaler
English: 6 capsules + 1 inhaler
Estonian: 6 kapslit + 1 inhalaator
English: 12 capsules + 1 inhaler
Estonian: 12 kapslit + 1 inhalaator
English: Anticholinergic effects related to glycopyrronium
Estonian: Antikolinergilised toimed seoses glükopürrooniumiga Kitsa nurga glaukoom
English: Inhaler base
Estonian: Inhalaatori põhi
English: Health-related quality of life:
Estonian: Tervislik seisnud:
English: 10 capsules + 1 inhaler
Estonian: 10 kapslit + 1 inhalaator
English: Adverse reactions
Estonian: Üldised häired
English: No effects on the embryo or foetus were seen at any dose level of Ultibro Breezhaler during an embryo-foetal development study in rats.
Estonian: Ühegi Ultibro Breezhaleri annuse korral ei täheldatud toimet rottide prenataalsele arengule.
English: Steady-state exposure to glycopyrronium after Ultibro Breezhaler inhalation was similar to systemic exposure after glycopyrronium monotherapy product inhalation.
Estonian: Pärast Ultibro Breezhaleri inhalatsiooni oli glükopürrooniumi tasakaalukontsentratsioon vereplasmas sarnane või veidi madalam kui pärast glükopürrooniumi monoteraapiana inhaleerimist.
English: Trough and peak FEV1:
Estonian: Minimaalne ja maksimaalne FEV1:
English: Inhalation use only
Estonian: Ainult inhalatsiooniks
English: Cap
Estonian: Põhi
English: Hepatic impairment
Estonian: KOKi ägenemine
English: • feeling of pressure or pain in the cheeks and forehead - these may be signs of inflammation of the sinuses called sinusitis.
Estonian: • survetunne ja valu põskedes ja otsmikul - need võivad olla ninakõrvalkoobaste põletiku nähud,
English: - you have thyroid gland problems (thyrotoxicosis).
Estonian: - kui teil on probleeme kilpnäärmega (türeotoksikoos).
English: When to inhale Ultibro Breezhaler
Estonian: Millal Ultibro Breezhalerit sisse hingata
English: Ultibro Breezhaler - glycopyrronium
Estonian: Ultibro Breezhaler - glükopürroonium
English: Myalgia
Estonian: Tahhükardia
English: Breathlessness:
Estonian: Glükopürroonium:
English: Glycopyrronium After intravenous administration of [
Estonian: Glükopürroonium Pärast [
English: Mouthpiece
Estonian: Rasedus
English: Exercise tolerance
Estonian: Hooravimi kasutamine
English: See package leaflet for further information.
Estonian: Vaata lisateavet pakendi infolehest.
English: It could take approximately 45 seconds.
Estonian: Selleks võib kuluda ligikaudu 45 sekundit.
English: How much and how often to have
Estonian: Kui palju ja kui tihti
English: This can lead to death.
Estonian: See võib põhjustada surma.
English: This information supplements sections 3 and 5 for the user.
Estonian: See informatsioon täiendab kasutajale mõeldud lõike 3 ja 5.
English: • You will usually have an infusion once every 3 weeks.
Estonian: • Tavaliselt saate infusiooni iga 3 nädala järel.
English: These effects were partially reversible after 8 weeks.
Estonian: Need toimed olid osaliselt pöörduvad 8 nädala pärast.
English: Other appropriate symptomatic measures should be taken.
Estonian: Tuleb rakendada teisi asjakohaseid sümptomaatilisi meetmeid.
English: Let this solution stand for approximately 5 minutes and check then that the solution is homogeneous and clear.
Estonian: Laske sel lahusel seista ligikaudu 5 minutit ning kontrollige seejärel, et lahus on homogeenne ja selge.
English: The following information is intended for healthcare professionals only.
Estonian: Järgmine teave on ainult tervishoiutöötajale:
English: • short term hair loss (in most cases normal hair growth should return)
Estonian: • lühiajaline juustekaotus (enamikul juhtudel juuste normaalne kasv taastub);
English: 6/ 18 weeks
Estonian: 6/18 nädalat
English: In this case, the solution must not be used and should be discarded.
Estonian: Sellisel juhul ei tohi lahust kasutada ja see tuleb hävitada.
English: 7/ 21 weeks
Estonian: 7/21 nädalat
English: If this happens, do not drive or use any tools or machines until you feel better.
Estonian: Sel juhul ärge juhtige autot või kasutage masinaid või mehhanisme enne, kui tunnete ennast paremini.
English: See a doctor immediately if you notice any of the following side effects:
Estonian: Pöörduge kohe arsti poole kui märkate mõnda järgnevat kõrvaltoimet:
English: Your doctor will monitor your blood and general condition for signs of infections.
Estonian: Arst jälgib teie vere ja üldist seisundit infektsiooni nähtude osas.
English: • you have fever.
Estonian: • kui teil on palavik.
English: Treatment should be delayed until improvement of symptoms.
Estonian: Ravi tuleb edasi lükata kuni sümptomite paranemiseni.
English: Median number of cycles/ median duration of treatment
Estonian: Mediaanne tsüklite arv/ mediaanne ravi kestus
English: Tell your doctor immediately if:
Estonian: Teavitage otsekohe oma arsti:
English: INFORMATION IN BRAILLE Justification for not including Braille accepted.
Estonian: Põhjendus Braille mitte lisamiseks aktsepteeritud
English: • The usual dose depends on your body surface area.
Estonian: • Tavaline annus sõltub teie kehapindalast.
English: Patients should be observed closely for hypersensitivity reactions especially during the first and second infusions.
Estonian: Patsiente tuleb hoolikalt jälgida ülitundlikkusreaktsioonide suhtes, eriti esimese ja teise infusiooni ajal.
English: Please tell your doctor, pharmacist or nurse if you are taking or have recently taken any other medicines.
Estonian: Teatage oma arstile, apteekrile või meditsiiniõele, kui te kasutate või olete hiljuti kasutanud või kavatsete kasutada mistahes muid ravimeid.
English: Early use of supportive care measures may help improve the condition.
Estonian: Toetavate ravimeetmete varajane kasutamine võib seisundit parandada.
English: Patients should receive therapeutic G-CSF as soon as possible after discovery of overdose.
Estonian: Patsientidele tuleb manustada G-CSF'i nii ruttu kui võimalik pärast üleannustamise avastamist.
English: Adverse reactions are listed in table 2 according to MedDRA system organ class and frequency categories.
Estonian: Kõrvaltoimed on loetletud Tabelis 2 vastavalt MedDRA organsüsteemi klassidele ja sageduskategooriatele.
English: • you have ever had any allergies.
Estonian: • kui teil on esinenud allergia.
English: The mean AUC was 991 ng.h/ml (CV: 34%).
Estonian: Keskmine AUC oli 991 ng.h/ml (CV: 34%).
English: From a microbiological point of view, the two-step dilution process must take place in controlled and aseptic conditions (see below “Preparation and administration precautions”).
Estonian: Mikrobioloogilisest seisukohast tuleb kahe-etapiline lahjendamisprotsess teostada kontrollitud ja aseptilistes tingimustes (vt allpool „Eritingimused valmistamiseks ja manustamiseks“).
English: The earliest sign of infection may be fever, so if you experience fever, tell your doctor right away.
Estonian: Infektsiooni kõige varasem näht võib olla palavik, seetõttu teavitage otsekohe oma arsti kui teil tekib palavik.
English: The patient should be advised to report any significant change in daily urinary volume immediately.
Estonian: Patsientidele tuleb soovitada, et nad teavitaksid koheselt ööpäevase uriinikoguse olulisest muutumisest.
English: • you have blood in your urine.
Estonian: • kui teie uriinis on verd.
English: Other medicines and JEVTANA
Estonian: Muud ravimid ja JEVTANA
English: If any of the above applies to you, tell your doctor immediately.
Estonian: Kui ülalnimetatu kehtib teie kohta, teavitage sellest kohe oma arsti.
English: Physicians should assess for the presence or worsening of neuropathy before each treatment.
Estonian: Arstid peavad hindama neuropaatia olemasolu või halvenemist enne igat ravitsüklit.
English: The name of your medicine is JEVTANA.
Estonian: Teie ravimi nimi on JEVTANA.
English: 13.4 (12.19 to 14.88)
Estonian: 13,4 (12,19 kuni 14,88)
English: Killed or inactivated vaccines may be administered; however, the response to such vaccines may be diminished.
Estonian: Surmatud või inaktiveeritud vaktsiine võib manustada, kuid ravivastus neile vaktsiinidele võib olla nõrgem.